These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

967 related articles for article (PubMed ID: 15359211)

  • 21. Medical management of patients with difficult-to-treat inflammatory bowel disease.
    van Hogezand RA
    Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: induction therapy for patients with active ulcerative colitis.
    Travis SP
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():10-6. PubMed ID: 16939424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current therapeutic possibilities in chronic inflammatory intestinal diseases].
    Schölmerich J
    Praxis (Bern 1994); 1995 Jan; 84(2):29-33. PubMed ID: 7839043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Local or systemic treatment of inflammatory bowel diseases?].
    Schmassmann A; Halter F
    Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K; Fischer C; Klotz U; Heinkel K
    Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conventional medical management of inflammatory bowel disease.
    Burger D; Travis S
    Gastroenterology; 2011 May; 140(6):1827-1837.e2. PubMed ID: 21530749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MMX mesalamine.
    Baker DE
    Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ulcerative colitis: responding to the challenges.
    Achkar JP
    Cleve Clin J Med; 2007 Sep; 74(9):657-60. PubMed ID: 17879519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Aminosalicylates in chronic inflammatory intestinal diseases and rheumatoid arthritis].
    Maier KP
    Dtsch Med Wochenschr; 1992 Oct; 117(42):1614-5. PubMed ID: 1356747
    [No Abstract]   [Full Text] [Related]  

  • 31. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
    Kruis W; Bar-Meir S; Feher J; Mickisch O; Mlitz H; Faszczyk M; Chowers Y; Lengyele G; Kovacs A; Lakatos L; Stolte M; Vieth M; Greinwald R
    Clin Gastroenterol Hepatol; 2003 Jan; 1(1):36-43. PubMed ID: 15017515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
    Cohen RD; Woseth DM; Thisted RA; Hanauer SB
    Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
    Feagan BG
    Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
    [No Abstract]   [Full Text] [Related]  

  • 34. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
    Osterman MT; Lichtenstein GR
    Methods Find Exp Clin Pharmacol; 2009; 31(1):41-6. PubMed ID: 19357797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD; Das KM
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Salazosulfapyridine and 5-aminosalicylic acid agents for the treatment of ulcerative colitis].
    Aihara H; Hiwatashi N
    Nihon Rinsho; 1999 Nov; 57(11):2476-80. PubMed ID: 10572415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing therapy for inflammatory bowel disease.
    Robinson M
    Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
    Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [5-aminosalicylic acid for induction of remission or clinical response in Crohn's disease--a survey of a Cochrane review].
    Bjerrum JT; Munck LK; Nielsen OH
    Ugeskr Laeger; 2011 Aug; 173(35):2110-3. PubMed ID: 21884660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.